Abstract | CONTEXT: OBJECTIVE: The objective of this study was to evaluate the effects of 6 months of metformin administration on endothelial structure and function in women with PCOS. DESIGN: This was a prospective, baseline-controlled, clinical study. SETTING: The study was performed at University Federico II (Naples, Italy). PATIENTS: INTERVENTIONS:
Metformin (850 mg daily) was administered for 6 months. MEAN OUTCOME MEASURES: RESULTS:
After treatment, SHBG levels and the free androgen index changed significantly (P < 0.001). High-density lipoproteins and the area under curve for glucose/area under curve for insulin ratio also significantly (P < 0.001) increased, whereas low-density lipoproteins and plasma endothelin-1 levels were significantly (P < 0.001) reduced. No other change was found in any of the biochemical parameters evaluated. A significant difference was observed in brachial artery baseline diameter (3.24 +/- 0.30 vs. 3.0 +/- 0.30), flow-mediated dilation (14.30 +/- 1.90 vs. 15.70 +/- 1.50) (P < 0.01, each), diameter after reactive hyperemia (3.70 +/- 0.30 vs. 3.55 +/- 0.10) (P < 0.05), and intima media thickness (0.53 +/- 0.09 vs. 0.40 +/- 0.07) (P < 0.001) after metformin treatment in comparison with baseline values. CONCLUSIONS: A 6-month course of metformin improves endothelial structure and function in young, normal-weight women with PCOS.
|
Authors | Francesco Orio Jr, Stefano Palomba, Teresa Cascella, Biagio De Simone, Francesco Manguso, Silvia Savastano, Tiziana Russo, Achille Tolino, Fulvio Zullo, Gaetano Lombardi, Ricardo Azziz, Annamaria Colao |
Journal | The Journal of clinical endocrinology and metabolism
(J Clin Endocrinol Metab)
Vol. 90
Issue 11
Pg. 6072-6
(Nov 2005)
ISSN: 0021-972X [Print] United States |
PMID | 16118336
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Endothelin-1
- Hypoglycemic Agents
- Metformin
|
Topics |
- Area Under Curve
- Cardiovascular Diseases
(etiology)
- Endothelin-1
(blood)
- Endothelium, Vascular
(pathology, physiopathology)
- Female
- Humans
- Hypoglycemic Agents
(therapeutic use)
- Insulin Resistance
- Metformin
(therapeutic use)
- Polycystic Ovary Syndrome
(complications, drug therapy, metabolism, pathology)
- Prospective Studies
|